Results 171 to 180 of about 40,069 (236)

Demographic Characteristics, Contributing Risk Factors, and Prognosis of <i>Acanthamoeba</i> Keratitis in Eastern China: An in vivo Confocal Microscopy-Based Fifteen-Year Study. [PDF]

Clin Ophthalmol
Lu C, Wang J, Hong J, Xu J, Zhou X, Tian L, Le Q.   +6 more
europepmc   +1 more source

<i>Acanthamoeba</i> keratitis in a tertiary referral hospital in central China: demographics, risk factors, clinical presentation, treatments and outcomes. [PDF]

Int J Ophthalmol
Wang JS, Zhao D, Yao TY, Jiang XY, Xie HT, Zhang MC.   +5 more
europepmc   +1 more source

A double-masked, sham-controlled trial of rose bengal photodynamic therapy for the treatment of fungal and acanthamoeba keratitis: Rose Bengal Electromagnetic Activation with Green Light for Infection Reduction (REAGIR) study. [PDF]

Trials
Prajna NV, Lalitha P, Sharma S, de Freitas D, Höfling-Lima A, Varnado N, Abdelrahman S, Cavallino V, Arnold BF, Lietman TM, Rose-Nussbaumer J.   +10 more
europepmc   +1 more source

Comparison of therapeutic effects between big-bubble deep anterior lamellar keratoplasty and penetrating keratoplasty for medically unresponsive Acanthamoeba keratitis. [PDF]

BMC Infect Dis
Qi X, Mao H, Liu J, Dong Y, Du M, Liu T, Zhang T, Lu X, Gao H.   +8 more
europepmc   +1 more source

Staurosporine as a Potential Treatment for Acanthamoeba Keratitis Using Mouse Cornea as an Ex Vivo Model. [PDF]

Mar Drugs
Rodríguez-Expósito RL, Sifaoui I, Salazar-Villatoro L, Bethencourt-Estrella CJ, Fernández JJ, Díaz-Marrero AR, Sutak R, Omaña-Molina M, Piñero JE, Lorenzo-Morales J.   +9 more
europepmc   +1 more source

Treatment of <i>Acanthamoeba</i> keratitis with high dose PHMB (0.08%) monotherapy in clinical practice: A case series. [PDF]

Eur J Ophthalmol
Franch A, Knutsson KA, Pedrotti E, Fasolo A, Bertuzzi F, Birattari F, Bonacci E, Leon P, Papa V.   +8 more
europepmc   +1 more source